Literature DB >> 33528821

Optic neuropathy in a patient with COVID-19 infection.

Patricia Rodrigo-Armenteros1, Juan María Uterga-Valiente1, Juncal Zabala-Del-Arco2, Silvia Taramundi-Argüeso3, Lander Antón-Méndez4, Juan José Gómez-Muga4, Juan Carlos Garcia-Monco5.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33528821      PMCID: PMC7852464          DOI: 10.1007/s13760-021-01600-w

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.471


× No keyword cloud information.

Introduction

COVID-19 has been associated with a variety of neurological disorders whose type and frequency are being defined, and include anosmia/ageusia, dizziness, confusion, agitation, headache and stroke [1]. Cranial neuropathies have been occasionally reported, mainly in the form of smell and taste dysfunction, oculomotor paresis, and facial palsy [2]. Peripheral neuropathies have also been described [3]. The optic nerve is not usually involved in SARS-CoV-2 infection. We here report a case of unilateral optic neuropathy in a patient with a severe pulmonary and encephalopathic presentation of COVID-19.

Case report

A 62-year-old male, with left eye amblyopia since childhood was admitted in March 2020 for an 8-day history of fever and upper respiratory tract symptoms. Nasopharyngeal reverse transcriptase polymerase chain reaction (RT–PCR) for SARS-CoV-2 was positive and he had hypoxemia and a bilateral interstitial pneumonia. He received hydroxychloroquine (200 mg twice-daily) for 7 days and Lopinavir–Ritonavir (200 mg/50 mg twice-daily) for 15 days. He developed a severe respiratory distress syndrome and was treated with dexamethasone (20 mg daily for 5 days) and tocilizumab (600 mg) with progressive improvement but developed an encephalopathy secondary to nonconvulsive status epilepticus that has been described elsewhere[4]. Blood tests showed an intense systemic inflammatory response with c-reactive protein of 309 mg/L (normal, < 10 mg/L), lactic dehydrogenase 613 U/L (< 280 U/L), ferritin 5700 ng/mL (< 300 ng/mL), and D-dimer 9550 ng/mL (< 250 ng/mL). Aquaporin-4 and myelin–oligodendrocyte protein (MOG) antibodies were negative. A lumbar puncture showed normal CSF opening pressure and biochemistry values. RT-PCR for SARS-CoV-2 in the CSF was negative. Cranial MRI on day 21 showed focal leptomeningeal enhancement in the right parietal peri-Rolandic sulci. There were also unexpected signs of left pre-chiasmatic optic inflammation (Fig. 1).
Fig. 1

Brain MRI findings. Brain MRI on day 21 (left panel). Coronal (a, b) and axial (c, d) contrast-enhanced FLAIR images of a brain MRI. Hyperintensity of the pre-chiasmatic cisternal segment of the left optic nerve (arrows) consistent with optic neuritis, along with focal high-intensity content in right parietal peri-rolandic sulci (arrowheads), as a sign of focal leptomeningitis. Furthermore, a diffuse dural enhancement can be noted, consistent with a recent lumbar puncture. Follow-up brain MRI on day 35 (right panel). Coronal (a, b) and axial (c, d) contrast-enhanced FLAIR images of a brain MRI, all of them at the same level as the findings described in Fig. 2. Persistence of mild optic neuritis signs can be noted (a, b). We can also appreciate the resolution of the dural enhancement, and a normal LCR signal intensity content in peri Rolandic sulci, consistent with disappearance of focal leptomeningitis (c, d)

Brain MRI findings. Brain MRI on day 21 (left panel). Coronal (a, b) and axial (c, d) contrast-enhanced FLAIR images of a brain MRI. Hyperintensity of the pre-chiasmatic cisternal segment of the left optic nerve (arrows) consistent with optic neuritis, along with focal high-intensity content in right parietal peri-rolandic sulci (arrowheads), as a sign of focal leptomeningitis. Furthermore, a diffuse dural enhancement can be noted, consistent with a recent lumbar puncture. Follow-up brain MRI on day 35 (right panel). Coronal (a, b) and axial (c, d) contrast-enhanced FLAIR images of a brain MRI, all of them at the same level as the findings described in Fig. 2. Persistence of mild optic neuritis signs can be noted (a, b). We can also appreciate the resolution of the dural enhancement, and a normal LCR signal intensity content in peri Rolandic sulci, consistent with disappearance of focal leptomeningitis (c, d) He did not complain of visual symptoms. Funduscopic examination was normal. Pupillary response to light was normal. Visual evoked potential latency was normal in the right eye (104 s), but was delayed in the left eye (124.9 s). Electroretinography showed an absent response on the left eye, and a normal one on the right eye; these findings indicate that the left eye was functionally blind. The patient was discharged on day 21 with a normal neurological exam. Brain MRI on day 45 showed resolution of the meningeal enhancement with persistence of the pre-chiasmatic optic neuritis image. Cranial nerve involvement, mainly ocular motor palsies may occur in COVID-19[2], but optic nerve involvement is rare [5]. Bilateral optic neuritis has been reported in association with myelitis in a SARS-CoV-2 patient with serum anti-MOG antibodies [6]. However, our patient had unilateral involvement without evidence of disseminated CNS involvement, and was seronegative for MOG and aquaporin-4. A recent report described a COVID-19 patient with posterior optic neuropathy but normal inflammatory markers [7]. The fact that this patient suffered left eye amblyopia with limited visual acuity since childhood likely explains that he did not complain of optic neuritis symptoms, despite a prolonged P100 latency. This was corroborated by the absence of response in electroretinography. The mechanism of optic nerve damage in this patient is unclear. Given his normal ophthalmologic exam, a posterior neuropathy in the context of active COVID-19 is more likely. A direct viral damage is not supported, given the normal CSF parameters and the absence of viral RNA in the CSF. A para-infectious mechanism involving the CNS in a similar fashion to that proposed for the delayed occurrence of Miller–Fisher syndrome and Gullain–Barre syndrome in SARS-CoV-2 and in other infections is more likely [2]. In some of these patients the presence of serum anti-GD1b antibodies may have a pathogenic role. Also, an inflammatory systemic reaction associated to SARS-CoV-2 infection, as suggested by an increased D-dimer and other inflammatory parameters in our patient, could have resulted in thromboembolic phenomena with occlusion of capillaries feeding the optic nerve. In conclusion, optic nerve inflammation may be associated with SARS-CoV-2 infection and may go unnoticed in patients with prior amblyopia.
  7 in total

Review 1.  Neuro-ophthalmic manifestations of coronavirus disease 19.

Authors:  Alanna K Tisdale; Bart K Chwalisz
Journal:  Curr Opin Ophthalmol       Date:  2020-11       Impact factor: 3.761

2.  Cranial neuropathies and COVID-19: Neurotropism and autoimmunity.

Authors:  Fiona Costello; Marinos C Dalakas
Journal:  Neurology       Date:  2020-06-02       Impact factor: 9.910

3.  Acute Vision Loss in a Patient with COVID-19.

Authors:  Vijairam Selvaraj; Daniel Sacchetti; Arkadiy Finn; Kwame Dapaah-Afriyie
Journal:  R I Med J (2013)       Date:  2020-06-10

4.  Neurologic Manifestations in a Prospective Unselected Series of Hospitalized Patients With COVID-19.

Authors:  Juan Carlos García-Moncó; Antonio Cabrera Muras; Markel Erburu Iriarte; Patricia Rodrigo Armenteros; Alejandra Collía Fernández; Javier Arranz-Martínez; Solange Kapetanovic; Ana Lorenzo-García; Amaia Bilbao González; Marian Gomez-Beldarrain
Journal:  Neurol Clin Pract       Date:  2021-04

5.  Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis and Myelitis in COVID-19.

Authors:  Siwei Zhou; Edward C Jones-Lopez; Deepak J Soneji; Christina J Azevedo; Vivek R Patel
Journal:  J Neuroophthalmol       Date:  2020-09       Impact factor: 3.042

Review 6.  Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing.

Authors:  Marinos C Dalakas
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-06-09

7.  Non-convulsive status epilepticus in a patient with COVID-19 infection.

Authors:  Patricia Rodrigo-Armenteros; Juan María Uterga-Valiente; Juncal Zabala-Del-Arco; Silvia Taramundi-Argüeso; Markel Erburu-Iriarte; Lander Antón-Méndez; Juan José Gómez-Muga; Juan Carlos Garcia-Monco
Journal:  Clin Neurophysiol       Date:  2020-08-26       Impact factor: 3.708

  7 in total
  2 in total

1.  Optic neuropathy in a COVID-19 patient.

Authors:  L Borrego-Sanz; N Guermes-Villahoz; F Fernández-Tresguerres; E Santos-Bueso
Journal:  J Fr Ophtalmol       Date:  2021-07-08       Impact factor: 0.818

Review 2.  COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era.

Authors:  Arens Taga; Giuseppe Lauria
Journal:  J Peripher Nerv Syst       Date:  2022-03-14       Impact factor: 5.188

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.